FDA
-
-
-
-
-
-
-
Precision BioSciences reports enhanced DMD gene therapy efficacy in younger mice
-
-
-
-
-
-
-
Precision BioSciences Announces Late-Breaking Poster Presentation for PBGENE-HBV at European Association for the Study of the Liver Congress 2026
-
-
-
-
-
-
-
Precision BioSciences shows muscle improvements in DMD gene therapy study
-
-
-
-
-
-
-
Precision BioSciences sets 2026 priorities for hepatitis B and DMD programs
-
-
-
-
-
-
-
Precision BioSciences gets FDA orphan drug status for DMD treatment
-
-
-
-
-
-
-
Precision BioSciences (DTIL) Receives U.S. FDA Fast Track Designation for PBGENE-HBV
-
-
-
-
-
-
-
Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
-
329,957 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

